The present invention provides enteric polymer coated tablet formulations
for oral administration which comprise a phospholipase A2 enzyme
Lipoprotein Associated Phospholipase A2 (Lp-PLA2) inhibitor, processes
for preparing such formulations and their use in therapy, in particular
the treatment of atherosclerosis.